Page 2 - Bortezomib News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bortezomib. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bortezomib Today - Breaking & Trending Today

Highlights from ASH 2023 in Transplant-Eligible NDMM

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies. ....

Multiple Myeloma , Newly Diagnosed Multiple Myeloma , Mm Treatment , Transplant Eligible , Griffin Trial , Perseus Trial , Maintenance Therapy , Mash 2023 ,

This Frontline Therapy Is Better in Multiple Myeloma: Study

A study directly comparing real-world outcomes suggests patients with transplant-ineligible multiple myeloma do better with frontline triple therapy with daratumumab vs bortezomib. ....

United States , Dorisk Hansen , American Society Of Hematology , National Comprehensive Cancer Network , Moffitt Cancer Center Research Institute In Tampa , Moffitt Cancer Center , Research Institute , American Society , Multiple Myeloma , Plasma Cell Myeloma , Monoclonal Antibody , Biologic Therapy , Proteasome Inhibitor , Transplantation Of Stem Cells , Ransplantation Of Hematopoietic Stem Cells , Hematopoietic Stem Cell Transplant , Stem Cell Transplantation , Stem Cell Therapy , Tem Cell Haematopoietic Stem Transplant ,

Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity

'This [research] builds on our experience that four-drug combinations with a monoclonal antibody, proteasome inhibitor, immunomodulatory drug, and steroids are superior to three-drug combinations.' ....

United States , Dana Farber Cancer Institute , Bristol Myers Squibb Celgene , Joseph Mikhael , Irene Ghobrial , City Of Hope Cancer Center , American Society Of Hematology , University Of Torino , International Myeloma Foundation , Division Of Hematology , Translational Genomics Research Institute Tgen , Health Sciences , Department Of Molecular Biotechnology , Translational Genomics Research Institute , Hope Cancer Center , American Society , Francesca Gay , Molecular Biotechnology , Medical Oncology , Bristol Myers , Multiple Myeloma , Plasma Cell Myeloma , Biologic Therapy , Monoclonal Antibody , Proteasome Inhibitor , Autologous Stem Cell Transplant ,

D-VRd Improves PFS in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Induction therapy with subcutaneous daratumumab followed by autologous stem cell transplant, daratumumab, bortezomib, lenalidomide, and dexamethasone consolidation and daratumumab/lenalidomide maintenance prolonged progression-free survival in patients with newly diagnosed, transplant-eligible multiple myeloma. ....

Subcutaneous Daratumumab , Autologous Stem Cell Transplant , Nd Dexamethasone Consolidation , Daratumumab Lenalidomide Maintenance , Patients With Newly Diagnosed , Transplant Eligible Multiple Myeloma , Perseus Trial , Pieter Sonneveld , Erasmus Mc Cancer Institute ,

Belantamab Mafodotin Plus Bortezomib/Dexamethasone Improves PFS in R/R Multiple Myeloma

Belantamab mafodotin plus bortezomib and dexamethasone significantly improved progression-free survival compared with daratumumab plus B-Vd in the second-line treatment of patients with relapsed or refractory multiple myeloma, meeting the primary end point of the phase 3 DREAMM-7 trial. ....

European Medicines Agency , European Commission , Medicinal Produces , Human Use , Multiple Myeloma , Belantamab Mafodotin Blmf , Relapsed Or Refractory Multiple Myeloma , Dreamm 7 Trial ,